358 related articles for article (PubMed ID: 18720197)
21. Nonionic surfactant-based vesicular system for transdermal drug delivery.
Ghanbarzadeh S; Khorrami A; Arami S
Drug Deliv; 2015 Dec; 22(8):1071-1077. PubMed ID: 24400680
[TBL] [Abstract][Full Text] [Related]
22. Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes.
Manosroi A; Khanrin P; Lohcharoenkal W; Werner RG; Götz F; Manosroi W; Manosroi J
Int J Pharm; 2010 Jun; 392(1-2):304-10. PubMed ID: 20381599
[TBL] [Abstract][Full Text] [Related]
23. In vitro skin permeation of estradiol from various proniosome formulations.
Fang JY; Yu SY; Wu PC; Huang YB; Tsai YH
Int J Pharm; 2001 Mar; 215(1-2):91-9. PubMed ID: 11250095
[TBL] [Abstract][Full Text] [Related]
24. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats.
Shah H; Nair AB; Shah J; Bharadia P; Al-Dhubiab BE
Daru; 2019 Jun; 27(1):59-70. PubMed ID: 30701460
[TBL] [Abstract][Full Text] [Related]
25. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain.
Abdelbary GA; Aburahma MH
J Liposome Res; 2015; 25(2):107-21. PubMed ID: 25058447
[TBL] [Abstract][Full Text] [Related]
26. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
Al-Mahallawi AM; Abdelbary AA; Aburahma MH
Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
[TBL] [Abstract][Full Text] [Related]
27. A novel vesicular transdermal delivery of nifedipine - preparation, characterization and in vitro/in-vivo evaluation.
Yasam VR; Jakki SL; Natarajan J; Venkatachalam S; Kuppusamy G; Sood S; Jain K
Drug Deliv; 2016; 23(2):619-30. PubMed ID: 25005581
[TBL] [Abstract][Full Text] [Related]
28. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery.
Gupta M; Vaidya B; Mishra N; Vyas SP
Artif Cells Blood Substit Immobil Biotechnol; 2011 Dec; 39(6):376-84. PubMed ID: 21951195
[TBL] [Abstract][Full Text] [Related]
29. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
[TBL] [Abstract][Full Text] [Related]
30. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies.
El-Laithy HM; Shoukry O; Mahran LG
Eur J Pharm Biopharm; 2011 Jan; 77(1):43-55. PubMed ID: 21056658
[TBL] [Abstract][Full Text] [Related]
31. Span and Tween neutral and pH-sensitive vesicles: characterization and in vitro skin permeation.
Carafa M; Marianecci C; Rinaldi F; Santucci E; Tampucci S; Monti D
J Liposome Res; 2009; 19(4):332-40. PubMed ID: 19863168
[TBL] [Abstract][Full Text] [Related]
32. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes.
Mokhtar M; Sammour OA; Hammad MA; Megrab NA
Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery.
Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
Int J Pharm; 2005 Jul; 298(1):55-67. PubMed ID: 15941634
[TBL] [Abstract][Full Text] [Related]
34. Drug compartmentalization as strategy to improve the physico-chemical properties of diclofenac sodium loaded niosomes for topical applications.
Tavano L; de Cindio B; Picci N; Ioele G; Muzzalupo R
Biomed Microdevices; 2014 Dec; 16(6):851-8. PubMed ID: 25129111
[TBL] [Abstract][Full Text] [Related]
35. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs.
Song S; Tian B; Chen F; Zhang W; Pan Y; Zhang Q; Yang X; Pan W
Drug Dev Ind Pharm; 2015 Jan; 41(1):51-62. PubMed ID: 24111828
[TBL] [Abstract][Full Text] [Related]
36. Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes.
Dubey V; Mishra D; Nahar M; Jain V; Jain NK
Nanomedicine; 2010 Aug; 6(4):590-6. PubMed ID: 20093197
[TBL] [Abstract][Full Text] [Related]
37. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery.
El Zaafarany GM; Awad GA; Holayel SM; Mortada ND
Int J Pharm; 2010 Sep; 397(1-2):164-72. PubMed ID: 20599487
[TBL] [Abstract][Full Text] [Related]
38. Development and in vitro permeation studies of proniosomal based transdermal delivery system of Atenolol.
Ramkanth S; Chetty CM; Sudhakar Y
Pak J Pharm Sci; 2014 Jan; 27(1):115-20. PubMed ID: 24374439
[TBL] [Abstract][Full Text] [Related]
39. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity.
Qumbar M; Ameeduzzafar ; Imam SS; Ali J; Ahmad J; Ali A
Biomed Pharmacother; 2017 Sep; 93():255-266. PubMed ID: 28738502
[TBL] [Abstract][Full Text] [Related]
40. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation.
Thakur R; Anwer MK; Shams MS; Ali A; Khar RK; Shakeel F; Taha EI
J Drug Target; 2009 Jul; 17(6):442-9. PubMed ID: 19527115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
